HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2147 Anti-mouse CXCR3 (CD183)-InVivo Anti-mouse CXCR3 (CD183)-InVivo reacts with mouse CXCR3 also known as CD183, a 38 kDa chemokine receptor for CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (ITAC). Feb 05 2024
A2148 Anti-mouse GM-CSF-InVivo Anti-mouse GM-CSF-InVivo reacts with mouse granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony stimulating factor 2 (CSF2). Feb 05 2024
A2149 Anti-mouse CD19-InVivo Anti-mouse CD19-InVivo reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. Feb 05 2024
E1287 SB 204990 SB-204990, a γ-lactone prodrug of SB-201076, is a potent and specific inhibitor of ATP citrate lyase (ACLY). SB 204990 potently limits SARS-CoV-2 replication in vivo. Feb 04 2024
E1721 TJ-M2010-5 TJ-M2010-5 is a small molecule inhibitor of MyD88 that selectively binds to the Toll/Interleukin-1 receptor (TIR) domain of MyD88, disrupting its homodimerization and subsequently inhibiting the Toll-like receptor (TLR)/MyD88 signaling pathway. TJ-M2010-5 exhibits an anti-hepatic fibrosis effect with the potential to treat liver fibrosis. Feb 04 2024
E1713 FL118 FL118(10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin analog, is a potent and orally active inhibitor of Survivin. FL118 also selectively and independently inhibits three additional cancer-associated survival genes Mcl-1, XIAP, and cIAP2 in a p53 status-independent manner. FL118 displays potent antitumor activity and can be used in cancer research. Feb 04 2024
E1655 KT 474 KT-474 (SAR444656) is a selective small-molecule degrader of IRAK4 in development for the treatment of TLR/IL-1R–driven autoimmune diseases. KT-474 potently downregulates R848 (TLR7/8) and lipopolysaccharide (LPS)-induced IL-6 and IL-8 production in peripheral blood mononuclear cells (PBMCs). Feb 01 2024
E1627 BMS493 BMS493 is an inverse agonist of pan retinoic acid receptor (RAR). It increases nuclear corepressor interaction with RARs and can be used as an inhibitor for the dietary and pharmacologic manipulation of retinoic acid (RA) activity in vivo and in vitro. Feb 01 2024
E1685 D609 D609 is a selective, competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC) with a Ki of 6.4 μM. It is an antioxidative protector and has antiviral and anti-inflammatory activity and also inhibits angiogenesis by preventing the synthesis of basement membrane (BM). Feb 01 2024
E1748 HG6-64-1 HG6-64-1 (HMSL 10017-101-1) is a highly potent and selective inhibitor of B-Raf with an IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells. Feb 01 2024
E1874 Erastin2 Erastin2 is an inducer of ferroptosis. It also selectively inhibits xc(-) cystine/glutamate transporter. It induces ferroptosis in HT-1080, T98G, and A549 cells with the potential to treat neurodegenerative diseases. Feb 01 2024
E1520 NSC 663284 NSC 663284(DA-3003-10) is a potent, cell-permeable, and irreversible dual specificity phosphatase inhibitor of Cdc25, and exhibits an IC50 of 0.21 μM for Cdc25B2 and is 20 and 450-fold highly selective against Cdc25B2. NSC 663284 also inhibits NSD2 with an IC50 of 170 nM via a direct interaction with the catalytic SET domain. Jan 30 2024
E1750 XST-14 XST-14 is a potent, competitive, and highly selective inhibitor of ULK1 and exhibits an IC50 of 26.6 nM in an in vitro ULK1 kinase activity assay, respectively. XST-14 reduces the phosphorylation of the ULK1 downstream substrate and induces autophagy inhibition. It exhibits antitumor effects. Jan 30 2024
E1832 ZK53 ZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP). It exhibits an EC50 of 1.37 μM for α-casein hydrolysis by HsClpP. ZK53 treatment allosterically activates HsClpP to uncontrollably degrade the essential mitochondrial proteins and is inactive toward bacterial ClpP proteins. Jan 30 2024
S9852 Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both. Jan 24 2024
E1749 limertinib limertinib (ASK120067) is an irreversible third-generation inhibitor of EGFRT790M with IC50 of 0.3 nM, with selectivity over EGFRWT having IC50 of 6.0 nM. It exhibits potent anti-proliferation activity in non-small cell lung cancer (NSCLC) tumor cells. Jan 23 2024
E4449 AG 825 AG-825 (Tyrphostin AG-825) is a potent and selective inhibitor of ErbB2 with IC50 values of 0.15 µM. It also inhibits PDGFR autophosphorylation with IC50 value of 40 µM. It exhibits anti-cancer activity and significantly induces apoptosis in cancer cells. Jan 22 2024
E1810 dCeMM1 dCeMM1 is a degrader of RBM39. dCeMM1 functions by altering the activity of the CRL4DCAF15 ligase, and also decreases RBM39 expression levels in wild-type KBM7 cells. Jan 22 2024
E1752 JNJ-42226314 JNJ-42226314 is a potent, selective, and reversible noncovalent inhibitor of monoacylglycerol lipase (MAGL). It enhances the expression of endocannabinoid 2-arachidonoylglycerol (2-AG) and exhibits antinociceptive efficacy in models of neuropathic and inflammatory pain. Jan 22 2024
E4453 Cathepsin G Inhibitor I Cathepsin G Inhibitor I exhibits reversible, competitive cathepsin G inhibition with IC50 and Ki values of 53 nM and 63 nM respectively. It can be used in antigen-processing studies and for modulation of T cell response in situ and in vivo. Jan 22 2024